Connect with us

Small Caps

SANUWAVE Health, Inc. (OTCBB:SNWV): Can it Maintain the Trend

Published

on

SANUWAVE Health, Inc. (OTCBB:SNWV) has been on the move in recent months moving up off$0.05 lows to recent highs near $0.2

SNWV was originally incorporated as Rub Mucis Enterprises, Inc., in Nevada on May 6, 2004 and was focused on becoming a music library business that established a catalogue of copyrighted songs that they intended to license. In November 2009 they changed their name to SANUWAVE Health, Inc.,

SANUWAVE Health, Inc. (OTCBB:SNWV) is a shock wave technology company focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.

SNWV initial focus is regenerative medicine – utilizing noninvasive, acoustic shockwaves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures.

The Company’s lead regenerative product in the United States is the demaPACE ® device, which is in a supplemental Phase III clinical study for treating diabetic foot ulcers with possible FDA approval in 2016, subject to submission of satisfactory clinical study results. dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand.

SANUWAVE has a number of partnership opportunities as well for their shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Co-CEO Kevin A. Richardson, II said on dermaPACE® PMA Submission: We had a great meeting with the FDA in June to determine a clear path to approval for our dermaPACE device for treatment of diabetic foot ulcers. At the meeting, the FDA agreed with our plan to analyze additional secondary endpoints in conjunction with the previously approved statistical analysis plan. FDA stated that they will look at the totality of the trial results, taking into account primary and secondary endpoints, safety, and benefit/risk assessments while reviewing a subsequent approval submission. Based on our meeting with the FDA, we are very encouraged that should the results of this trial mirror that of the previous trial, we can provide a clinically significant set of results in a PMA for the FDA’s approval consideration.

 To Find out the inside Scoop on SNWV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The DMC will perform an analysis on the entire 130 patient population once the patients have completed the twelve week efficacy analysis period. This is expected to be completed in the first quarter of 2015. After their review of the 130 patients, the DMC may recommend: 1) stopping enrollment because the dermaPACE has met the minimum success criteria as compared to sham-control, 2) increasing enrollment to 170 patients which is the next predefined patient analysis point, or 3) stopping the trial due to poor results.

Kevin Richardson, II, Chairman of the board of directors of SANUWAVE, stated, “We are very pleased to have reached this enrollment milestone in the supplemental clinical trial of dermaPACE to treat diabetic foot ulcers. We anticipate having the feedback from the Data Monitoring Committee regarding the 130 patients in the first quarter of 2015 and look forward to updating shareholders at that time.”

 

Recently the Company announced in partnership with Ortho-Medico, a member of B&Co, Herzele, Belgium, is sponsoring continuing clinical investigation on diabetic foot ulcers (DFU). This trial is expected to begin in January 2017, and will be conducted by the VUB (Free University of Brussels) and UZ Brussel (University Hospital). Earlier work in 2015 at this hospital found that DFU patients, treated in-home with dermaPACE system, responded positively to the treatment. This trial will take the home-care procedures, used in a limited basis, and extend them to a randomized, controlled trial of 100 subjects. The intent of this trial is to compare the effectiveness of in-home treatment of diabetic foot ulcers (DFUs) using dermaPACE as compared to in-home treatment of DFUs using standard of care only. This trial will help to provide evidence that dermaPACE can be used outside the clinical setting and in essence increase the potential for expanded sales in Europe.

Currently trading at an $23.3 million market valuation SNWV does have a strong cash position of $1.6 million in the treasury, manageable debt and small but fast growing revenues. SNWV traded as high as $5 shortly after hitting the bb’s with many seed shareholders paying well over $2 a share. SNWV is an exciting story developing in small caps (especially from current price levels) they are in the midst of top line data analysis for their treatment of foot ulcers; dermaPACE and expect to have preliminary results for the public in early October. We will be updating on SNWV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SNWV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SNWV either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Plandai Biotechnology Inc (OTCMKTS: PLPL) Breaking Out Northbound after Closing on the “Smart Hotel” EV Hotel Corp Reverse Merger

Published

on

Plandai Biotechnology Inc (OTCMKTS: PLPL) is breaking out northbound up over 30% on $300,000 in dollar volume in the first 2 hours of trading on Thursday. The move comes as the incoming CEO of with EV Hotel Corp., announced the Company closed on the acquisition of 100% stock of EV Hotel Corp., with the official announcement coming next Tuesday. Plandai also plans to file with the SEC, Finra and OTC Markets Group for both a formal name and symbol change to reflect the new direction and identity of the Company. 

EV Hotel™ has developed the world’s first proprietary disruptive hospitality platform – the “smart hotel,” combining technology, automation, IoT, and crypto with best-in-class service, stylish design, and upscale amenities to deliver a more efficient hotel operation, happier guests, and more streams of revenue. EV Hotel™ CEO Ken Patel states: “I came to set the ultimate goal to revolutionize the hospitality industry like never before. Now one item is checked off and many more to achieve.” 


Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Plandai Biotechnology Inc (OTCMKTS: PLPL) is a perfect reverse merger candidate with just $420,000 in total liabilities and no note payables or convertible debt on the books having previously massively diluted the stock. Reverse merger SPACS can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars. Two recent RM runners that stand out are TSNP/HMBL which went from sub pennies (where we first wrote about it) to several dollars per share. The other is HRBR which went from a few cents (where we first wrote about it) to $3 plus.

The incoming Company: EV Hotel™ developed the world’s first proprietary disruptive hospitality platform – the “smart hotel,” combining technology, automation, IoT, crypto and NFT with best-in-class service, stylish design, and upscale amenities to deliver a more efficient hotel operation, happier guests, and more streams of revenue. EV Hotel™ revolutionizes how hotels operate by streamlining the guest experience, with thoughtful technologies that eliminate frustrating chokepoints across the guest journey, reimagining the hotel front desk with streamlined check in from its proprietary EV Smart™ app, automating hotel operations, providing upscale amenities, and building new revenue streams which provides a central control point over the guest experience including room controls, concierge, room service and more. The EV Smart™ app provides an all-in-one solution that provides for a seamless guest experience. 

Image

To Find out the inside Scoop on PLPL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PLPL

EV Hotel’s™ “IoT Smart Rooms” incorporates technologies allowing guests to relay requests directly into hotel service allowing hotel staff to see and respond in real-time, based on device-specific data, automatically providing alerts about problems reducing guest disruptions and out-of-service rooms and eliminating the need for preventative maintenance, saving both labor and equipment costs, all while providing significant energy savings. 

EV Hotel™ operates a franchise model and it’s first franchisee is obtaining permits and converting a 63-year-old 114 room Travelodge into Phoenix, Arizona’s first ever smart hotel. It will be a new, cutting-edge hotel in a historically designated building. The design preserves the historic building and transforms it into the city’s first fully automated smart hotel with a hip pool that will mirror a trendy Miami style vibe. 

EV Hotel™ also feature NFT (non-fungible token) artwork that is available for purchase in the hotel’s NFT Lobby and in its designer rooms, featuring one-of-a-kind NFT pieces for sale. Each guest owns their rewards via an NFT purchase, which allows them to sell their entire membership – with its rewards intact – to other travelers. EV Hotel™ is the first hospitality brand with integrated cryptocurrencies, with a dedicated Crypto experience center and trading floor backed by CDX and a special Crypto ballroom.The Parties are conducting due diligence with the intent to finalize a material definitive agreement outlining terms and conditions. Plandai expects its independent two-year audit to be finalized very soon and will form the basis for its operations going forward. 

For More on PLPL Subscribe Right Now!

Currently trading at a $6.6 million market valuation PLPL OS is 7,343,911,205 with 5,176,257,801 shares in the float. PLPL is a clean shell with just $420k in total liabilities and no note payables or convertible debt on the books. Back in 2014 a year when penny stocks and cannabis stocks especially made spectacular moves, PLPL was among the biggest runners of them all spiking up to over $3 per share at the time. A lot has happened since then including whipping $20 million in debt off the books via massive dilution over the years. PLPL today represents an exciting opportunity in small caps; the Company has just closed on 100% stock of EV Hotel Corp., with the official announcement coming next Tuesday. Plandai also plans to file with the SEC, Finra and OTC Markets Group for both a formal name and symbol change to reflect the new direction and identity of the Company. The “smart hotel,” EV Hotel™ operates a franchise model and it’s first franchisee is obtaining permits and converting a 63-year-old 114 room Travelodge into Phoenix, Arizona’s first ever smart hotel. According to this article “There are 11 locations planned for EV Hotel around the world, with the first set to open in Phoenix by the end of 2022 or early 2023, Patel said in a previous interview with Asian Hospitality. The rest are planned in California, Florida and elsewhere, with corporate headquarters in Atlanta. Mr. Patel said at closing: “I came to set the ultimate goal to revolutionize the hospitality industry like never before. Now one item is checked off and many more to achieve.” PLPL is quickly attracting a growing shareholder base that swears this one goes way higher. Microcapdaily will be covering PLPL / EV Hotel™ as it happens so make sure you subscribe to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PLPL either long or short and we have not been compensated for this article.

Continue Reading

Emerging Markets

Digital Brand Media & Marketing Group, Inc. (OTCMKTS: DBMM) Running as Company Meets Requirements to Trade in US and Short Covering Rally Intensifies

Published

on

Digital Brand Media & Marketing Group, Inc. (OTCMKTS: DBMM) tripled on Thursday after the Company announced they are now compliant with FINRA Rule 6432 and have met the requirements under that rule to initiate a quotation for DBMM within four days of 10/26/2022. For Shareholders, this means the company has been approved to resume trading. Glendale Securities is the company’s sponsoring broker to FINRA and its designated Market Maker. The Form 211 clearance to resume trading has taken place. The removal of the OTC Market’s icon, CE follows the resumption as next step. In the interim, the market is cleared. This means US shareholders can buy and sell. The restriction for US buyers has been lifted.  

DBMM is another short squeeze from Kramer and Asher of GTII fame which blew up from $0.50 to just under $9 per share in recent months as the shorts got taken to the cleaners. DBMM is an SEC filer and will have the skull & crossbones designation removed from OTCmarkets and be eligible for trading from the US within days. DBMM is also a revenue generating Company that continue to see significant growth reporting $164,000 in sales for the 3 months ended May 31, 2022 up from $120,000 for the same period last year. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Digital Brand Media & Marketing Group, Inc. (OTCMKTS: DBMM) operating out of NYC, New York and London, Uk operates through its wholly owned subsidiaries including Stylar Limited dba Digital Clarity. The Company is a multi-service digital marketing agency which specializes in creating effective strategies and campaigns for clients across a range of vertical markets, working in four key areas: 

  • Search Engine Marketing – for search engines like Google, Yahoo Microsoft Bing 
  • Analytics – measuring and analyzing web traffic to optimize performance. 
  • Strategy & Consulting – digital transformation and marketing strategy. 
  • Social Media – planning and measuring social metrics digitally in order to diagnose strategy. 

DBMM Group can leverage its team’s experience in digital media and provide leading strategy, deployment and measurement to its core markets in many industry sectors, from creative to traditional corporate. The vertical B2B sectors encompass areas such as B2B ecommerce, SaaS, Blockchain, Fintech, Software Sales and Technology. 

The Company is rolling out the services of both the technology and marketing services offerings from its operating base in the UK with a plan to increase its presence into the larger markets in the US. namely Los Angeles and New York. The intent in fiscal year 2022 will be a strategy of cash infusion to immediately correlate to increased revenues. Growth is clearly a function of available capital. Fiscal year 2021 reflected the Company’s continued progress by being awarded contracts for a number of new clients, in the midst of a very challenging year because of external factors beyond the Company’s control, specifically the pandemic and the SEC Matter awaiting the Commission’s final affirmation of the dismissal. The contract model strategy results in a full digital technology and marketing consultancy from design following an analysis of the client’s analytics, then executing and stewarding the evolution of the model. The Company’s mantra is “ROI is our DNA,” the underlying focus for business development. According to the Company’s 10k filed on November 5, 2021 DBMM has 7 full-time employees as of August 31, 2021. 

To Find out the inside Scoop on DBMM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DBMM

On October 27 DBMM announced that on October 26, 2022 FINRA processed a Form 211 relating to the initiation of priced quotations of DBMM, which means that the submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and therefore has met the requirements under that rule to initiate a quotation for DBMM within four days of 10/26/2022. FINRA’s processing of a Form 211 in no way constitutes FINRA’s approval of the security, the issuer, or the issuer’s business and relates solely to the submitting broker-dealer’s obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security.” 

For Shareholders, this means the company has been approved to resume trading. Glendale Securities is the company’s sponsoring broker to FINRA and its designated Market Maker. The Form 211 clearance to resume trading has taken place. The removal of the OTC Market’s icon, CE follows the resumption as next step. In the interim, the market is cleared. 

This means US shareholders can buy and sell. The restriction for US buyers has been lifted. Shareholders are also advised to do their own Due Diligence and hence ignore nonsense, opinions, and misinformation. Read FINRA 6532 regulations yourselves and SEC 15c2-11. Compliance has been fulfilled. This action represents another step forward; resuming normal trading is resuming normal business. Another update will be issued in 2-3 days according to DBMM Management. 

https://twitter.com/MotorCityTweet/status/1585719971778174977

 For More on DBMM Subscribe Right Now!

Currently trading at a $1.8 million market valuation DBMM has a ton of room for growth from here. As DBMM goes back to “pink current” and can be purchase by US investors and shorts begin to cover this entire situation could blow up into a whole new stratosphere. As stated DBMM is another short squeeze from Kramer and Asher of GTII fame which blew up from $0.50 to just under $9 per share in recent months as the shorts got taken to the cleaners. Speculators are looking for DBMM to follow a similar course as GTII. We will be updating on DBMM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DBMM either long or short and we have not been compensated for this article.

Continue Reading

Media & Technology

Street Watch

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.